The Role of the Pharmacist in Pre-Exposure Prophylaxis


Pre-exposure prophylaxis is a new HIV prevention method that has shown to be effective in HIV uninfected persons at very high risk of HIV infection. It involves daily use of truvada in combination with other proven methods of HIV prevention. The aim of this paper is to discuss the various roles that pharmacists play in pre-exposure prophylaxis to maximize therapy.

Share and Cite:

Matyanga, C. (2014) The Role of the Pharmacist in Pre-Exposure Prophylaxis. Pharmacology & Pharmacy, 5, 225-228. doi: 10.4236/pp.2014.53029.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Cohen, M.S. and Baden, L.R. (2012) Pre-exposure Prophylaxis for HIV—Where Do We Go from Here? New England Journal of Medicine, 367, 5.
[2] Thigpen, C.M., Kebaabetswe, P.M., Paxton, L.A., Smith, D.K., Rose, C.E., Segolodi, T.M., et al. (2012) Antiretroviral Pre-Exposure Prophylaxis for Heterosexual HIV Transmission in Botswana. New England Journal of Medicine, 367, 423-434.
[3] Baeten, J.M., Donnell, D., Ndase, P., Mugo, N.R., Campbell, J.D., Wangisi, J., et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine, 367, 399-410.
[4] Grant, R.M., Lama, J.R., Anderson, P.L., McMahan, V., Liu, A.Y., Vargas, L., et al. (2010) Pre-Exposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine, 363, 2587-2599.
[5] Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P.A., Leethochawalit, M., et al. (2013) Antiretroviral Prophylaxis for HIV Infection in Injecting Drug Users in Bangkok, Thailand (The Bangkok Tenofovir Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet, 381, 2083-2090.
[6] FDA Approves First Medication to Reduce HIV Risk.
[7] Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., et al. (2012) Pre-Exposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine, 367, 411-422.
[8] Press Release. Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study.
[9] Nichols-English, G. and Poirier, S. (2000) Optimizing Adherence to Pharmaceutical Care Plans. Journal of the American Pharmaceutical Association, 40, 475-485.
[10] (2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach.
[11] Clauson, K.A., Polen, H.H., Joseph, S.A. and Zapantis, A. (2009) Role of the Pharmacist in Pre-Exposure Chemoprophylaxis (PrEP) Therapy for HIV Prevention. Pharmacy Practice (Internet), 7, 11-18.
[12] (2012) Investigator’s Brochure: Truvada® (Emtricitabine/Tenofovir Disoproxil Fumarate) Tablets. Gilead Sciences, Foster City.
[13] CDC (2011) Characteristics Associated with HIV Infection among Heterosexuals in Urban Areas with High AIDS Prevalence—24 Cities, United States, 2006-2007. MMWR, 60, 1045-1049.
[14] (2012) Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults. MMWR, 61, 586-589.
[15] (2013) Proven HIV Methods. Centers for Disease Control and Prevention.
[16] Santschi, V., Chiolero, A., Burnand, B., Colosimo, A.L. and Paradis, G. (2011) Impact of Pharmacist Care in the Management of Cardiovascular Disease Risk Factors: A Systematic Review and Meta-Analysis of Randomized Trials. Archives of Internal Medicine, 171, 1441-1453.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.